LLY - Eli Lilly's Alzheimer's Drug Donanemab Faces FDA's Adcomm Vote Next Week On Data Risk Profile | Benzinga
On Monday, June 10, the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee will meet to discuss and vote on whether the data from Eli Lilly And Co’s (NYSE:LLY) Phase 3 Study AACI (TRAILBLAZER-ALZ 2) support a favorable benefit-risk assessment for the use of donanemab for Alzheimer’s disease.
In March last year, Eli Lilly released the results of the TRAILBLAZER-ALZ 2 Phase 3 study of donanemab for Alzheimer’s disease.
The document notes that the phase ...